Spotlight On: Prolia® / Xgeva® (denosumab) / Jubbonti® / Wyost® (denosumab-bbdz) / Ospomyv™ / Xbryk™ (denosumab-dssb) / Stoboclo® / Osenvelt® (denosumab-bmwo) / Conexxence™ / Bomyntra™ (denosumab-bnht)
by Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.
March 31, 2025



Download PDF
*Denosumab Challenged Claim Types in Litigation: Claims are counted in each litigation, so claims from the same patent challenged in multiple litigations are counted more than once. Within each litigation a claim is counted only once. Claims in litigations are determined based on claims alleged to be infringed or invalid in Complaints.
Click on the “Subscribe” link above for access to future product dashboards and updates.